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ABSTRACT 
Objectives: To investigate the association between PTEN loss and IGFBP2 expression in a series of 
triple-negative breast cancers and to relate this expression to basal cytokeratin expression and 
clinicopathologic features. 
Methods: One hundred and one formalin-fixed and paraffin-processed triple-negative breast cancer 
cases from the University of Malaya Medical Centre were tested immunohistochemically for cytokeratins 
5/6 and 14, PTEN, and IGFBP2. The resulting slides were scored for proportion and intensity of staining. 
Results: Loss of tumor nuclear and cytoplasmic staining for PTEN occurred in 48.3% of cases and was 
significantly associated with younger age at diagnosis (47 years compared with 57 years in those without 
PTEN loss; P = .005). Independent predictors of PTEN loss were late stage at presentation (P = .026), 
 2 
cytokeratin 5/6 positivity (P = .028), and IGFBP2 expression (P = .042). High levels of IGFBP2 
expression were seen in 32% of cases; independent predictors of high levels were cytokeratin 14 
negativity (P = .005). PTEN loss and high levels of IGFBP2 expression were associated with poorer 
survival but neither of these trends was significant. 
Conclusions: PTEN loss is a frequent event in triple-negative breast cancers and is significantly 
associated with younger age at onset of breast cancer, late stage, and IGFBP2 expression. 
Triple-negative (TN) breast cancers are defined by their lack of expression of the estrogen receptor (ER), 
progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2), and account for 10% to 24% of 
all breast cancers.
1-4
 Notably, TN breast cancers share many overlapping characteristics with basal-like breast 
cancers, in that the majority of TN breast cancers have elevated expression of high-molecular-weight cytokeratins 
and both have similar gene expression signatures.
5-9
 TN tumors are predominantly high-grade and aggressive 
cancers with poor prognosis, and unlike hormone receptor– and HER2-positive breast carcinomas, no targeted 
therapeutic regimens have been shown to significantly improve survival.
10
 The treatment of these tumors is therefore 
challenging and biomarker studies are required to better characterize these tumors with the aim of identifying 
improved therapeutic interventions. 
Phosphatase and tensin homolog (PTEN) is a tumor suppressor gene that is lost or mutated in many types of cancer, 
including breast, prostate, and lung cancer.
11
 PTEN dephosphorylates PIP3, a product of the PI3K pathway, thereby 
inactivating the Akt signaling pathway, inhibiting cell growth and promoting apoptosis.
11
 More recently, PTEN has 
been postulated to have an important role in DNA repair, because mutation or loss of PTEN results in a deficiency to 
repair DNA double strand breaks.
12
  
Although one previous study reported PTEN loss in 48% of unselected breast cancer cases,
13
 other studies have 
reported lower incidence of PTEN loss (8%, 15%, 28%).
13-15
 However, these differences may reflect methodologic 
differences in testing and reporting PTEN loss. In contrast, a recent study suggests that up to 66% of basal-like 
breast cancers have loss of PTEN, which may occur more frequently in this phenotype than in other subtypes of 
breast cancer.
15
 Insulin-like growth factor–binding protein 2 (IGFBP2) is a member of six binding proteins that 
modulate the action of insulin-like growth factors (IGF-I, IGF-II) that principally signal via the type 1 IGF receptor 
(IGF-IR).
16
 This axis plays a critical role in the development and progression of many epithelial cancers, including 
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breast cancer.
17
 At the cellular level, the IGF-I receptor appears to play a fundamental role in maintaining the 
transformed phenotype.
18
 Recent prospective epidemiologic studies have consistently shown strong associations 
between circulating IGF-I levels and the subsequent risk of developing a number of epithelial cancers, including 
breast cancer.
19
 Although IGFBPs can act to either inhibit or enhance IGF-induced cell signaling, they can also exert 
effects in an IGF-I–independent manner, indicating that IGFBPs can intrinsically modulate aspects of cell growth 
and survival.
20
 Busund et al
21
 reported that IGFBP2 abundance was markedly higher in invasive breast carcinoma 
and carcinoma in situ compared with normal breast tissue or benign hyperplastic lesions that had very little IGFBP2 
expression. Wang et al
22
 reported that tumor expression of IGFBP2 could predict tumors most likely to metastasize. 
IGFBP2 clearly appears to play a role in breast cancer progression,
21,23-26
 and interestingly, high levels of IGFBP2 
expression have also been identified in a number of additional cancers, including prostate,
27
 ovary,
28
 stomach,
29
 
adrenal gland,
30
 and bladder,
31
 suggesting that IGFBP2 generally plays an important role in tumorigenesis.  
An unbiased screen of human prostate and glioblastoma samples, using microarray-based expression profiling, 
identified IGFBP2 as the most significant marker of PTEN loss.
32
 Although the mechanism of loss of expression of 
PTEN in breast cancer has yet to be fully elucidated in cell lines, PTEN activity is downregulated by the interaction 
of IGFBP2 with the 1 integrin receptor.16 
The purpose of the current study was to investigate for the first time the association between PTEN loss and IGFBP2 
expression in a relatively large series of TN breast cancers and to relate this expression to basal cytokeratin 
expression and the clinicopathologic features of stage, histologic grade, patient age, and overall survival.  
Materials and Methods 
Tissue blocks of all accessible TN breast carcinomas diagnosed between 2004 and 2009 at the University of Malaya 
Medical Centre (Kuala Lumpur, Malaysia) were used in this study, with a total of 101 identified as having adequate 
invasive tumor tissue for evaluation. All tissues had been fixed in 10% neutral-buffered formalin for 6 to 72 hours, 
and processed to paraffin wax blocks, from which sections were cut at 3-μm thickness on a rotary microtome and 
mounted onto Tissue Tek Plus glass slides (Sakura, Alphen aan den Rijn, The Netherlands) to ensure maximum 
adhesion. 
Assessment of Tumor Grade and Stage: 
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Grading was performed according to the modified Bloom and Richardson criteria
33
 and all slides were reviewed and 
regraded for this study by the histopathologists on the team. [Au3: Pls include initials] Clinical data on patient 
age, ethnicity, and stage (American Joint Commission on Cancer, 2003) were extracted from the database for this 
series of cases. Patients were staged based on criteria described in the 6th edition of the American Joint Commission 
on Cancer (AJCC) guidelines.
34
 
Immunohistochemistry 
Expression of ER, PR, HER2, IGFBP2, PTEN, cytokeratins 5/6, and cytokeratin 14 was tested using standard 
immunohistochemical methods. Briefly, slides were deparaffinized, treated with 0.3% hydrogen peroxide to block 
endogenous peroxidase, and incubated for 30 minutes in a 750-W microwave oven in the appropriate antigen 
retrieval buffer to expose tissue antigens. The slides were then incubated in the respective primary antibodies 
overnight at 4C ❚Table 1❚. A horseradish peroxidase–conjugated avidin-biotin–based system was used for antibody 
detection and visualization (Vector Elite, Vector Laboratories, Peterborough, England). Nuclei were counterstained 
with Harris hematoxylin. The specificity of the IGFBP2 antibody was tested by adding a specific IGFBP2 blocking 
peptide (Santa Cruz Biotechnology, Dallas, TX) to the primary antibody mix before application. Positive cell line-
block controls for ER, PR, and HER2 were used as described previously.
35
 
Assessment of Immunohistochemistry 
Immunohistochemical staining for ER and PR was assessed with the Allred scoring system described in the most 
recent American Society of Clinical Oncology/College of American Pathologists guidelines.
36
 Briefly, nuclear 
staining of the invasive tumor cells was designated an intensity score (0 [no staining], 1 [weak staining], 2 [moderate 
staining], 3 [strong staining]) and a proportion score (0 [no staining], 1 [less than 1%], 2 [1%-10%], 3 [11%-33%], 4 
[34%-66%], 5 [67%-100%]). The intensity and proportion scores were then summed to give a total score ranging 
from 0 through 8, with a score of more than 2 defined as positive for ER or PR. The same scoring system was used 
to assess the cytoplasmic staining of IGFBP2 in the invasive tumor compartment, with a total score of 0, 2 to 5, and 
6 to 8 defined as no expression, low expression, and high expression of IGFBP2, respectively. For the purposes of 
comparing IGFBP2 expression with PTEN loss and other clinicopathologic variables, a cutoff of more than 5 was 
used to define IGFBP2 positivity. This cutoff was chosen based on the results of So et al (2008), [Au4: Pls 
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include So et al study in reference list] who showed that intermediate and strong staining of IGFBP2 
(which equates to an Allred score of >5) was associated with worse breast cancer–specific survival in hormone 
receptor–negative disease. Positivity for HER2 was defined as intense and complete membrane staining (chicken 
wire pattern) of at least 30% of invasive tumor cells.
37
 Most tumors were large and heterogeneous in nature with 
respect to PTEN expression. Consequently, PTEN expression was considered lost in cases of complete absence of 
staining (both cytoplasmic and nuclear) in at least two thirds of the invasive tumor compartment, with PTEN 
staining in the adjacent normal stromal tissue being used as the internal positive control. Cytokeratin 5/6 and 
cytokeratin 14 immunostaining was assessed on the basis of 10% or more invasive tumor cells showing cytoplasmic 
positivity, using appropriate localized staining of normal glands as positive internal controls. The basal-like 
phenotype was defined as positivity for cytokeratin 5/6 and/or cytokeratin 14.
8
 Cases that were not possible to 
interpret or did not have sufficient positive control staining were omitted from analysis. 
Follow-up Data 
At the University of Malaya Medical Centre, all patients were followed-up via scheduled appointments in the 
specialist breast cancer clinics. Data on mortality were obtained from the hospitals' medical records, as well as 
through active follow-up. In addition, vital status was verified through direct linkage with the National Registration 
Department in Malaysia. Follow-up time was calculated as the interval between date of diagnosis and date of death, 
or date of last contact, whichever came first.  
Statistical Analysis 
Continuous variables (age) were described using medians and compared using the Mann-Whitney U test; categorical 
variables (ethnicity, stage, grade, IGFBP2 expression, PTEN loss, cytokeratin 5/6 expression, and cytokeratin 14 
expression) were expressed as proportions and compared using either the 2 test or Fisher exact test. Variables 
significantly associated with PTEN loss and IGFBP-2 expression were simultaneously entered into a multivariate 
logistic regression model, with PTEN loss and IGFBP-2 as the outcome variables to determine the independent 
predictors of PTEN loss and IGFBP2 expression. Because information on cause of death was not available for most 
patients, we calculated relative survival rates (RSRs) to estimate the high mortality rate associated with breast cancer 
among the patient population.
36
 Population mortality data for Malaysia were used to compute these estimates. The 
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relative survival rate adjusts for the general survival of the Malaysian population for the given sex, age, and year, 
and thus is a measure of net survival attributed to breast cancer independent of other causes of death. P values of 
less than .05 were considered statistically significant, as was the 95% confidence interval (CI) for odds ratio (OR) 
that did not include 1.0. All statistical analyses were carried out using IBM Statistics software (version 20; IBM 
SPSS, Armonk, NY) and Stata MP (version 14) software (StataCorp, College Station, TX). 
Results 
Following retesting of ER, PR, and HER2 and confirmation of the  TN status of the breast cancers, 89 cases were 
available for analysis of PTEN loss and basal cytokeratin expression and 100 cases for analysis of IGFBP2 and basal 
cytokeratin expression. Patient age at onset of breast cancer ranged from 23 to 83 years, with a median of 53 years. 
Most cases (93%) were invasive ductal carcinomas, with the remaining being either medullary or metaplastic 
cancers. Sixty-two percent of the tumors were of basal-like phenotype based on their positive expression of 
cytokeratin 5/6 and/or cytokeratin 14.  
PTEN 
PTEN staining occurred in both the nucleus and cytoplasm of cancer cells. Loss of nuclear-cytoplasmic 
immunostaining for PTEN occurred in 48.3% of TN cases; the remaining cases had weak PTEN staining or stronger 
staining of PTEN equal to that of the surrounding stromal tissue ❚Image 1❚. Univariate [Au5: ok? Is this what 
you mean?] analysis showed that loss of PTEN immunostaining was associated with younger age at onset; the 
median age of patients at diagnosis with tumors showing PTEN loss was 47 years, compared with 57 years in those 
without PTEN loss (P = .005). PTEN loss was also associated with expression of cytokeratin 5/6 and IGFBP2, but 
these trends were not statistically significant on univariate analysis (P = .097 and P = .073, respectively). In 
multivariate analysis, independent predictors of PTEN loss were younger age at onset (P = .041), late stage (P = 
.026), cytokeratin5/6 positivity (P = .028), and IGFBP2 expression (P = .042) ❚Table 3❚, [Au6: Table 2 not 
cited. Pls cite before Table 3] ❚Image 2❚, and ❚Image 3❚. 
IGFBP2 
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IGFBP2 staining was predominantly confined to the cytoplasmic compartment of the invasive cancer cells with little 
stromal staining or expression in normal glands. Addition of the IGFBP2 blocking peptide resulted in complete 
absence of staining in cases shown to be strongly positive for IGFBP2 ❚Image 4❚. Of 100 TN cases that were 
assessable for IGFBP2 staining, 32% showed high levels of IGFBP2 expression (Allred score >5). Univariate 
analysis revealed no significant differences in high IGFBP2 expression and age, stage, or cytokeratin 5/6 but 
IGFBP2 expression was associated with lack of staining for cytokeratin 14 (P = .004). Multivariate analysis showed 
that independent predictors of high levels of IGFBP2 expression were lack of positivity for cytokeratin 14 (P = .005) 
and PTEN loss (P = .047) ❚Image 5❚. There was also a trend for lymphovascular invasive cases to have high levels 
of IGFBP2 expression but this trend was not significant (P = .064). 
Survival Analysis 
TN cases with PTEN loss seem to have a poorer survival than cases without PTEN loss; the 4-year RSR for patients 
with PTEN loss was 65.0% (95% CI, 45.2%-79.7%) compared with 77.8% (95% CI, 60.8%-89.0%) in those without 
PTEN loss. Similarly, cases with high levels of IGFBP2 experienced marginally lower survival than their 
counterparts with low or negative IGFBP2; the 4-year RSR was 68.4% (95% C,: 44.5%-84.5%) for high levels of 
IGFBP2 compared with 74.9% (95% CI, 60.8%-85.1%) for cases with low or no IGFBP2 expression ❚Figure 1❚ and 
❚Figure 2❚. 
Discussion 
In the current study, PTEN expression in tumor cells is lost in nearly half of all TN breast cancers when tested using 
the antibody clone 6H2.1. Notably, the extent of PTEN loss in TN breast cancer is significantly higher than that 
reported using the same PTEN antibody in an unselected breast cancer cohort.
15
 Clone 6H2.1 is the recommended 
marker for immunohistochemical analysis of PTEN loss because it is the only antibody that exhibits a correlation 
with molecular alterations in PTEN
38
 and shows a correlation between western blot analysis and PTEN mutational 
and allelic status.
14
 Loss of PTEN staining in the invasive tumor compartment is readily assessable; strong positive 
staining of the adjacent nontumor stroma serves as an excellent internal positive control, as previously reported.
14
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Interestingly, loss of PTEN was significantly associated with a younger age at diagnosis. This reflects the findings 
by Anders et al
39
 that PTEN expression and genes involved in related signaling pathways were altered in breast 
cancers that occurred in younger patients (≤45 years).  
Although not significant, PTEN loss was associated with breast cancer survival; this is in agreement with the 
significant findings of Depowski et al
40
 in a cohort of breast cancers not selected on the basis of TN status. TN 
cohorts generally tend to have poorer survival than unselected cohorts of breast cancer cases. Consequently, it is 
probably necessary to study larger TN cohorts with PTEN loss to establish whether the trend observed in the current 
study becomes significant when larger numbers of cases are included.  
IGFBP2 positivity was associated with lymphovascular invasion and lower breast cancer survival rates. However, 
neither of these reached statistical significance, possibly because of the small number of cases in the current study. 
These data are consistent with those of So et al,
26
 who showed that of 3,117 breast tumors that were assessable for 
both ERα status and IGFBP2 expression, IGFBP2 was not prognostic among the ERα-positive tumors, but a trend 
showed lower breast cancer disease-specific survival rates in the ER-negative tumors. Furthermore, in vitro studies 
have demonstrated that overexpression of IGFBP2 in ER-negative breast cancer cell lines and cell lines of other 
cancer types that include those of prostate, glioma, and bladder conferred a growth advantage, enhanced invasion 
and migration, and chemoresistance.
22,26,31,41
 Interestingly IGFBP2 expression in tumors was linked to lack of 
staining for the basal cytokeratin 14. TN breast cancers are enriched for characteristics of epithelial mesenchymal 
transition and we speculate that these tumors may be undergoing epithelial mesenchymal transition. Further studies 
would be required to confirm this. A recent study showed that IGFBP2 promotes angiogenesis in neuroblastoma 
cells via direct activation of the vascular endothelial growth factor (VEGF) promoter
42
 and anti-VEGF therapy of 
gliomas; infiltrating tumor was associated with increased levels of IGFBP2.
43
 Because VEGF is already considered 
a target in TN breast cancer, perhaps cotargeting IGFBP2 might be of benefit. In addition, overexpression of EGFR 
and IGFBP2 has been observed in high-grade astrocytomas and coexpression of these genes was strongly associated 
with high-grade gliomas and lower survival. This report suggested that coexpression of these genes had a more 
important clinical and biological impact than the expression of each individual gene alone.
44
 EGFR is strongly 
associated with TN breast cancer and is a potential target
45,46
; there may now be a rationale for assessing EGFR 
status in relation to IGFBP2 expression in TN breast cancers because perhaps cotargeting both of these would 
provide a better outcome. 
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This is the first immunohistochemical study to show an association between IGFBP-2 expression and PTEN loss 
and supports the evidence from studies using in vitro cell lines that show IGFBP2 downregulates PTEN
16
 and 
conversely that overexpression of PTEN has been shown to reduce IGFBP2 expression.
47
 These studies indicate 
IGFBP2 plays a role in the PI3K signaling pathway that is known to be involved in promoting survival and 
growth.
48
 Several pathways could be responsible for this inverse relationship, including increased IGFBP2 
expression by breast cancer cells diminishing or ablating the expression of PTEN protein, potentially via integrin 
receptors.
16
 Further work could also investigate how IGFBP2 affects the catalytic activity of PTEN. PTEN possesses 
a carboxy-terminal, noncatalytic regulatory domain with three phosphorylation sites (Ser380, Thr382, and Thr383) 
that regulate its biological activity.
49,50
 Antibodies are available that recognize phosphorylation at these sites and 
may prove useful in further studies to investigate the relationship between IGFBP2 expression and PTEN 
phosphorylation and thus activity.
 
In summary, we have shown that loss of PTEN can be readily assessed using immunohistochemistry; that PTEN 
loss is a frequent event in TN breast cancers; and that this is significantly associated with a younger age at onset of 
breast cancer, late stage of presentation, and high levels of IGFBP2 expression. [Au7: Tables 4 and 5 not 
cited anywhere. Pls cite in numerical order]  
Address reprint requests to Dr Rhodes: Anthony.Rhodes@uwe.ac.uk. 
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❚Table 1❚ 
Antibodies and Antigen Retrieval 
Antibody Supplier Antigen Retrieval 
ER, clone 6F11 Novocastra, Newcastle-Upon-Tyne, England MW, Sodium citrate pH6.0 
PR (A & B), clone SP2 Lab Vision, Runcorn, England MW, Sodium citrate pH6.0 
HER2, clone SP3 Lab Vision  MW, Sodium citrate pH6.0 
Cytokeratin 5/6, clone D5/16B4 Dako, Ely, England MW, Tris-EDTA pH 9.0 
Cytokeratin 14, clone LL02 Novocastra  MW, Sodium citrate pH6.0 
PTEN, clone 6H2.1 Dako Ltd MW, Tris-EDTA pH 9.0 
IGFBP2, clone C-18 Insightbio, Middlesex, England MW, Sodium citrate pH6.0 
EDTA, ethylenediaminetetraacetic acid; ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; IGFBP2, insulin-like growth factor–binding protein 
2; MW, [Au8: Pls include expansion of MW] ; PR, progesterone receptor; PTEN, phosphatase and tensin homolog. 
 
❚Table 2❚ 
Factors Associated With PTEN Loss  
 Overall  PTEN Loss No PTEN 
Loss 
P for 2 Test 
No. (%) of patients 89 43  46   
Median age, y 53 47 57 .005a,b 
Ethnicity, No. (%)    .518c 
   Chinese 53 (59.6) 27 (62.8) 26 (56.5)  
   Malay 21 (23.6) 10 (23.3) 11 (23.9)  
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   Indian 12 (13.5) 6 (14.0) 6 (13.0)  
   Others 3 (3.4) 0 (0.0) 3 (6.5)  
Median tumor size, cm 3.0 3.5 3.0 .236b 
Lymph nodes involved, No. 
(%) 
   .250 
   Yes 42 (47.2) 23 (53.5) 19 (41.3)   
   No 47 (52.8) 20 (46.5) 27 (58.7)  
Stage, No. (%)    .078 
   Early (stage 1-2) 55(61.8) 23(53.5) 32(69.6)  
   Late (stage 3-4) 34(38.2) 20(46.5) 14(30.4)  
Grade,d No. (%)    .145 
   Grade 2 16 (18.6) 5 (12.2) 11(24.4)  
   Grade 3 70 (81.4) 36 (87.8) 34 (75.6)  
   Unknown 3  2 1  
Lymphovascular invasion, No. 
(%) 
   .780 
   Present 32 (40.5) 16 (42.1) 16 (39)  
   Absent 47 (59.5) 22 (57.9) 25 (61)  
   Unknown 10 5 5  
CK14 status, No. (%)    .354 
   Negative 47 (54) 20 (48.8) 27 (58.1)  
   Positive 40 (46) 21 (51.2) 19 (41.3)  
   Unknown 87 2 0  
 15 
CK 5/6 status, No. (%)    .097 
   Negative 23 (29.1) 8 (20.5) 15 (37.5)  
   Positive 56 (70.9) 31 (79.5)  25 (62.5)  
   Unknown 10 4 6  
IGBFP2, No. (%)    .073 
   Positivee 31 (34.8) 19 (44.2) 12 (26.1)  
   Negative 58 (65.2) 24 (55.8) 34 (73.9)  
CK, cytokeratin; IGFBP2, insulin-like growth factor–binding protein 2; PTEN, phosphatase and tensin homolog. 
a Statistically significant (P <.05). 
b Compared using the Mann-Whitney U test. 
c Compared using the Fisher exact test. 
d There were no patients with grade 1 tumor. 
e Defined as an Allred score of >5. 
 
❚Table 3❚ 
Factors Associated With PTEN Loss in Multivariate Analysis 
  95% CI for 
OR 
  
Factors OR for PTEN 
Loss (95% CI)a 
Lower Upper P Value 
Age, y 0.95b 0.91 1.00 .041 
Stage     
   Early (stage 1-2) 1.00c    
   Late (stage 3-4) 3.76b 1.17 12.10 .026 
Grade     
   Grade 2 1.00c    
   Grade 3 2.95 0.81 10.77 .101 
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CK 5/6 expression     
   No 1.00c    
   Yes 3.94b 1.16 13.34  .028 
IGBFP2 expression     
   No 1.00c    
   Yes 3.26b 1.04 10.21 .042 
CI, confidence interval; CK, cytokeratin; IGFBP2, insulin-like growth factor–binding protein 2; OR, odds ratio; PTEN, phosphatase and tensin homolog. 
a Derived using a multivariable logistic regression model including all variables with P < .20 in univariable analysis; age, stage, grade, CK 5/6, and IGBFP2 status. 
b Statistically significant (P < .05). 
c Reference category. 
 
❚Table 4❚ 
Factors Associated With High Levels of IGFBP2 Expressiona   
 Overall  IGFBP2-
Positive, No. 
(%) 
IGFBP2-
Negative, No. 
(%) 
P for 2 Test 
No. (%) of patients 100 32  68   
Median age, y 53 52 53 .685b 
Ethnicity    .215 
   Chinese 63 (63.0) 19 (59.4) 44 (64.7)  
   Malay 21 (21.0) 6 (18.8) 15 (22.1)  
   Indian 13 (13.0) 7 (21.9) 6 (8.8)  
   Others 3 (3.0) 0 (0.0) 3 (4.4)  
Median tumor size, cm 3.0 3.3 3.0 .445b 
Lymph node involved    .866  
   Yes 44 (44) 15 (42.9) 29 (44.6)  
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   No 56 (56)  20 (57.1) 36 (55.4)  
Stage    .837c 
   Early 65 (65) 24 (68.6) 41 (63.0)  
   Late 35 (35) 11(31.4) 24 (37.0)  
Graded    .855 
   Grade 2 19 (19.6) 7 (20.6) 12 (19)  
   Grade 3 78 (80.4) 27(79.4) 51 (81)  
   Unknown 3 1 2  
Lymphovascular invasion    .176 
   Present 34 (34.3) 16 (47.1) 18 (32.7)   
   Absent 55 (65.7) 18 (52.9) 37 (67.3)  
   Unknown 11 1 10  
CK14 status    .004 
   Negative 55 (56.7) 26 (76.5) 29 (46)  
   Positive 42 (43.3) 8 (23.5) 34 (54)  
   Unknown 3 1 2  
CK 5/6 status    .368 
   Positive 26 (29.5) 11 (35.5) 15 (26.3)  
   Negative 62 (70.5) 20 (64.5) 42 (73.7)  
   Unknown 12 4 8  
PTEN loss    .073 
   Yes 43 (48.3) 19 (61.3) 24 (41.4)  
   No 46 (51.7) 12 (38.7) 34(58.6)  
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   Unknown 11 1 10  
CK, cytokeratin; IGFBP2, insulin-like growth factor–binding protein 2; PTEN, phosphatase and tensin homolog. 
a Defined as an Allred Score >5. 
b Compared using the Mann-Whitney U test. 
c Compared using the Fisher exact test. 
d No patients with grade 1 tumor. 
 
 
❚Table 5❚ 
Factors Associated With IGFBP2 Positivity in Multivariate Analysis 
  95% CI for OR   
Factor OR for IGFBP2 
Positivity (95% 
CI)a 
Lower Upper P Value 
Lymphovascular 
invasion 
    
   Absent  1.00 b    
   Present 2.56 c 0.95 6.93 .064 
CK14 expression     
   No 1.00b    
   Yes 0.23c 0.08 0.64 .005 
PTEN loss     
   No 1.00    
   Yes 2.74 c 1.02 7.39 .047 
CI, confidence interval; CK, cytokeratin; IGFBP2, insulin-like growth factor–binding protein 2; OR, odds ratio; PTEN, phosphatase and tensin homolog. 
a Derived using a multivariate logistic regression model including all variables with P < .20 in univariate analysis, lymphovascular invasion, CK 14 expression, and 
PTEN loss. 
b Reference category. 
c Statistically significant (P < .05). 
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❚Image 1❚ Patterns of immunohistochemical staining for phosphatase and tensin homolog (PTEN) in three triple-
negative invasive ductal carcinomas (IDC). A, Cytoplasmic and nuclear staining of the IDC. B, Weak cytoplasmic 
and nuclear staining for PTEN in the IDC compared with strong staining in the surrounding stromal tissue. C, 
Absence of staining for PTEN in the IDC, indicating total loss of PTEN in the tumor compartment, with strong 
staining for PTEN in the adjacent stromal tissue. 
❚Image 2❚ A, Loss of immunohistochemical staining for phosphatase and tensin homolog (PTEN) in a triple-
negative invasive ductal carcinoma. B, Strong cytoplamic staining for cytokeratin 5/6 in the same tumor. 
❚Image 3❚ A triple-negative invasive ductal carcinoma (IDC) stained with H&E (A), the same IDC showing loss of 
PTEN staining (B) and strong cytoplasmic staining for insulin-like growth factor–binding protein 2 (IGFBP2) (C). 
❚Image 4❚ A, Immunohistocochemical cytoplasmic staining for insulin-like growth factor–binding protein 2 
(IGFBP2) in a triple-negative invasive ductal carcinoma. B, The addition of the IGFBP-2 blocking peptide resulted 
in complete absence of cytoplasmic staining for IGFBP2 in this tumor. 
❚Image 5❚ A, A triple-negative infiltrating ductal carcinoma immunohistochemically stained for insulin-like growth 
factor–binding protein 2 (IGFBP2). B, The same tumor immunohistochemically stained for cytokeratin 14; the 
normal glands stain positively, the invasive tumor component is negative. 
❚Figure 1❚ Relative survival by phosphatase and tensin homolog (PTEN) status.  
❚Figure 2❚ Relative survival by insulin-like growth factor–binding protein 2 (IGFBP2) status. 
